Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Monrol and FutureChem Announced a Clinical Supply Partnership
Details : 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 18, 2022
Lead Product(s) : 177-Lu EBTATE
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Molecular Targeting Technologies
Deal Size : Undisclosed
Deal Type : Agreement
MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.
Details : A timely and sustainable supply of a key therapeutic ingredient (n.c.a.177Lu) needed for the development and launch of company lead asset 177Lu-EBTATE and other EB platform technologies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 24, 2021
Lead Product(s) : 177-Lu EBTATE
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Molecular Targeting Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
